Rasagiline induced hypersexuality in Parkinson’s disease

Abstract Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson’s disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole [1–5] . Less evident is the possible association between monoamine oxidase inhibitors type...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2014-03, Vol.21 (3), p.507-508
Main Authors: Reyes, Dennys, Kurako, Kateryna, Galvez-Jimenez, Nestor
Format: Article
Language:English
Subjects:
Antiparkinson Agents - adverse effects
Disruptive, Impulse Control, and Conduct Disorders - chemically induced
Humans
Hypersexuality
Impulse control disorders
Indans - adverse effects
Male
Middle Aged
Neurology
Neuroprotective Agents - adverse effects
Parkinson Disease - drug therapy
Parkinson’s disease
Rasagiline
Sexual Dysfunctions, Psychological - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson’s disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole [1–5] . Less evident is the possible association between monoamine oxidase inhibitors type B (MAO-B) and the development of ICD [5] . Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. Rasagiline is effective and well tolerated in PD as a monotherapy or in combination with levodopa [6] . Here, we report a patient with PD who developed ICD when treated de novo with MAO-B inhibitors.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2013.04.021